500882-27-9

Usage

Uses

Used in Organic Synthesis:
Ethanesulfonamide, N-(3-aminophenyl)is utilized as a reagent in organic synthesis for the preparation of a variety of organic compounds. Its unique chemical properties make it a valuable component in the creation of diverse chemical entities.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Ethanesulfonamide, N-(3-aminophenyl)is explored as a potential candidate for the development of new drugs. Its ability to inhibit carbonic anhydrase suggests its use in conditions where modulation of this enzyme's activity could be therapeutically beneficial.
Used in Medical Research:
Ethanesulfonamide, N-(3-aminophenyl)is also employed in medical research to study its effects on various diseases. Ethanesulfonamide, N-(3-aminophenyl)-'s interaction with carbonic anhydrase and its potential implications in disease treatment make it a subject of interest for scientific investigation.

Upstream product

• 60901-25-9 ethanesulfonic acid (3-nitrophenyl)amide 
• 99-09-2 3-nitro-aniline 

Downstream Products

• 500882-28-0 1-(3-ethanesulphonamidophenyl)piperazine 
• 732242-10-3 ethanesulfonic acid {3-[4-(3-benzo[b]thiophen-3-yl-3-oxo-propyl)-piperazin-1-yl]-phenyl}-amide 

Relevant academic research and scientific papers

Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α1A-adrenoceptor agonist

Structure-activity studies were performed on the α 1A-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the α1A, α1b, α1d, α2a, and α2B subtypes. Functional activity in tissues containing the α1A (rabbit urethra), α1B (rat spleen), α1D (rat aorta), and α2A (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (MAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the α1A-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective α1-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater α1A selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the α1A-AR subtype in the control of MAP.

New 3-[4-(3-substituted phenyl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)-propanol derivatives with dual action at 5-HT1A serotonin receptors and serotonin transporter as a new class of antidepressants

In this paper a series of new 3-[4-(3-substituted phenyl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propanol derivatives is presented as a new class of antidepressant drugs with dual activity at 5-HT1A serotonin receptors and serotonin transporte